clinical trial · NCT03744403
A Study of CS1001 in Subjects with Advanced Solid Tumors
Advanced Solid TumorsCS1001
brief summary
This is a phase I, open-label, multiple-dose, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of CS1001 in subjects with advanced solid tumors.
started
Dec 4, 2018
primary completion
Oct 31, 2020
completion
Jul 21, 2021
last updated
Sep 19, 2024
official title
A Phase I, Open-Label, Multiple-Dose, Dose-Escalation Study of an Anti-PD-L1 Monoclonal Antibody CS1001 in Subjects with Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol